Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder
NCT07220460 · View on ClinicalTrials.gov ↗
Study Summary
Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population in the United States. The purpose of this study is to assess how safe and effective ABBV-932 is in treating participants with depressive episodes associated with bipolar I or II disorder. ABBV-932 is an investigational drug being developed for the treatment of depressive episodes in adult participants with bipolar I or II disorder. Participants with bipolar I or II disorder who are currently experiencing a depressive episode will enter the study and be treated with open-label ABBV-932. Approximately 200 adult participants with bipolar I or II disorder will be enrolled in approximately 50 sites in the United States and Puerto Rico. Participants will receive oral capsules of ABBV-932 for a 26-week treatment period. The treatment period will be followed by a safety follow-up (SFU) period of 30 days. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regularly scheduled visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Conditions Studied
Interventions
- DRUG ABBV-932
Study Locations (20)
California
- Advanced Research Center /ID# 273474 — Anaheim
- Axiom Research /ID# 273482 — Colton
- Collaborative Neuroscience Research - Garden Grove /ID# 273492 — Garden Grove
- Sun Valley Research Center /ID# 273472 — Imperial
- Synergy San Diego /ID# 278340 — Lemon Grove
- Alliance for Research Alliance for Wellness /ID# 273477 — Long Beach
- Nrc Research Institute - Los Angeles /ID# 278450 — Los Angeles
- Excell Research /ID# 273483 — Oceanside
- Inland Psychiatric Medical Group Inc. /ID# 273471 — Temecula
- Sunwise Clinical Research /ID# 278165 — Walnut Creek
Florida
- Cns Healthcare - Jacksonville /ID# 278332 — Jacksonville
- GMI Florida - Central Miami Medical Institute /ID# 273486 — Miami
- Allied Biomedical Res Inst Inc /ID# 273476 — Miami
- Floridian Clinical Research - Miami Lakes /ID# 279379 — Miami Lakes
- K2 Medical Research - Orlando - South Orlando Avenue /ID# 273487 — Orlando
- Apg Research /ID# 278439 — Orlando
- Segal Trials - West Broward Outpatient Research Site /ID# 273496 — Tamarac
- Health Synergy Clinical Research /ID# 279384 — West Palm Beach
Arizona
- Ima Clinical Research Phoenix (Alea) /ID# 278047 — Phoenix
Connecticut
- Connecticut Clinical Research - Cromwell /ID# 278116 — Cromwell
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-09-30 |
| Est. Completion | 2027-04 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07220460
The ClinicalTrials.gov registry entry for NCT07220460 describes a study currently listed as recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 603 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Bipolar I or II Disorder appearing as the primary indexed condition, and to 1 intervention — of which ABBV-932 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT07220460 reports 20 study locations spanning 4 distinct geographic areas — top geographies include California, Florida, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT07220460 about?
NCT07220460 is a clinical study titled "Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder". Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population in the United States. The purpose of this study is to assess how safe and effective ABBV-932 is in treating participants with depressive episodes associated with bipolar I or II disorder. ABBV-932 is an...
What is the current status of trial NCT07220460?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2025-09-30. Estimated completion is 2027-04.
What conditions does trial NCT07220460 study?
This clinical trial studies the following conditions: Bipolar I or II Disorder. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT07220460?
The interventions under investigation include: ABBV-932 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT07220460?
This trial is sponsored by AbbVie, which has 603 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT07220460 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.